Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term special drug use-results survey of Ongentys in Parkinson's disease
jRCT2011210013Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of opicapone in Parkinson's disease (PD), sponsored by Ono Pharmaceutical. Primary endpoints: Specified safety concerns (overall incidence of adverse drug reactions), Dyskinesia incidence and related factors and 2 more. Started Feb 2021; status: completed.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2011210013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210013.